Cell line · CVCL_6832
HCCLM3
Cancer cell line, Homo sapiens. Adult hepatocellular carcinoma. 33 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Cite this record
ConductScience Library. HCCLM3. Cell lines, record CVCL_6832. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_6832
On this page
Cell line
As Cellosaurus gives it.
- Name
- HCCLM3
- Accession
- CVCL_6832
- RRID
- RRID:CVCL_6832
- Synonyms
- HCCLM-3, HCC-LM3, LM3, MHCC-LM3, MHCCLM3
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 39Y
- Category
- Cancer cell line
- Diseases
- Adult hepatocellular carcinoma (NCIt C7956); Adult hepatocellular carcinoma (ORDO Orphanet_210159)
- Parent
- MHCC97-H (CVCL_4972)
- Secondary accessions
- CVCL_7679
- Entry created
- 2012-04-04
- Entry updated
- 2025-11-27
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers33
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| USP4-Dependent CHAF1B Stabilization Regulates Distinct SETDB1 Ubiquitin States Linked to AKT T308 Signaling and Lipogenic Remodeling in HCC. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FKBP52 dictates the dual role of p53 in hepatocellular carcinoma: Mutation-specific prognostic stratification and therapeutic implications. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Cuproptosis and Ferroptosis via a ROS-Responsive Nanoplatform for Enhanced Synergistic Therapy Against Hepatocellular Carcinoma. | Antioxidants (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The miR-4512/PDZK1IP1 axis in hepatocellular carcinoma: clinical significance, diagnostic value, and functional validation. | BMC Med Genomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CCT2 Orchestrates Glycolysis and Exosome-Mediated M2 Macrophage Polarization in HCC tumorigenesis. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ginkgolic acid targets HSPA8 to trigger ferroptosis in hepatocellular carcinoma via chaperone-mediated autophagy-dependent GPX4 degradation. | Pharm Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| β-catenin mutation reprograms ketone body metabolism to drive hepatocellular carcinoma metastasis and resistance to ketogenic therapy via transcriptional activation of OXCT1. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP1 promotes hepatocellular carcinoma progression by modulating mitophagy via stabilizing MCM3 to regulate the Keap1-Nrf2 axis. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic‒epigenetic axis. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PFKL Inhibition by DT-13: A Novel Approach to Combat Hepatocellular Carcinoma. | Int J Hepatol | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 33
See all 33 papersRelatives6
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Parent | MHCC97-H | CVCL_4972 | Cell lines | |
| Derived from it | HCCLM3-GFP-LC3 | CVCL_WJ13 | Cell lines | |
| Derived from it | HCCLM6 | CVCL_7680 | Cell lines | |
| Derived from it | HyCyte HCCLM3 KO-hGIHCG | CVCL_F1P0 | Cell lines | |
| Derived from it | HyCyte HCCLM3 KO-hHSPA4 | CVCL_D6B7 | Cell lines | |
| Derived from it | HyCyte HCCLM3 KO-hUSP22 | CVCL_D6B8 | Cell lines |
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| CCTCC | GDC0289 |
Source Cellosaurus
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_6832
GET https://conductscience.org/api/cell-lines/v1/CVCL_6832/papers?page=2